BIOLITEC RESEARCH GmbH

Their core work

BIOLITEC RESEARCH GmbH is a German SME based in Jena with expertise in photodynamic therapy and light-activated biomedical technologies — the company behind clinical photosensitizer compounds used in laser-based cancer treatment. Their H2020 participation was exclusively through Marie Skłodowska-Curie training networks, where they contributed as an industrial third party, providing research infrastructure and practical exposure for doctoral candidates. Their project involvement spans theoretical chemistry foundations (TCCM) and applied molecular container chemistry (NOAH), suggesting they bridge computational molecular modeling with real-world biomedical applications. This positions them as an industrial anchor in academic consortia rather than a grant-receiving research organization.

What they specialise in

How they've shifted over time

In their first H2020 engagement (TCCM, 2015–2018), BIOLITEC was embedded in a foundational computational chemistry training network with no specific application domain evident from available keywords. By their second project (NOAH, 2018–2022), their participation shifted toward functional molecular containers — structures relevant to controlled drug delivery, photosensitizer encapsulation, and switchable molecular systems. This progression from general computational chemistry toward targeted molecular engineering aligns with the logic of a photodynamic therapy company seeking to understand and eventually apply molecular container systems for drug or sensitizer delivery.

Their trajectory points toward molecular engineering of functional containers — a field directly relevant to next-generation drug delivery and photosensitizer encapsulation, suggesting future collaborations in supramolecular chemistry and precision medicine are a natural fit.

How they like to work

BIOLITEC participates exclusively as a third party in large MSCA training networks, meaning they contribute as an industrial host or knowledge provider without carrying a primary research budget. Their 36 unique partners across 12 countries from just two projects reflects the large-consortium structure typical of ITN/EJD programs, not a personal network they built independently. Working with them likely means they offer industrial secondments, practical use cases, or proprietary compound testing environments rather than co-leading research agendas.

Through two MSCA training networks, BIOLITEC has been exposed to 36 consortium partners spanning 12 countries — a broad European footprint relative to their project count. This network is MSCA-native, meaning it consists primarily of universities and research institutes rather than industry peers.

What sets them apart

BIOLITEC brings an unusual combination: a commercial photodynamic therapy company with documented engagement in doctoral-level training in supramolecular and computational chemistry. For consortium builders, this means access to a company that understands both laboratory-scale molecular science and clinical/regulatory pathways for light-activated therapeutics. As an SME industrial partner in MSCA networks, they add credibility to the commercialization track of research proposals without requiring large budget allocations.

Highlights from their portfolio

• NOAH
  A Joint European Doctorate network on molecular containers with switchable properties — directly relevant to drug delivery and encapsulation applications where BIOLITEC's photosensitizer expertise is commercially applicable.
• TCCM
  A flagship MSCA-EJD program in theoretical chemistry, signaling BIOLITEC's early investment in computational chemistry expertise as a foundation for their molecular design capabilities.